S

Sanofi

Global pharma company; vaccines and R&D

Policy and Government Affairs Intern

Summer 2027Updated Deadline 11/2/26
$27 - $57/hr
Internship
Washington, DC, USA
In PersonOnsite in Washington, DC; must relocate to the office and work 40 hours/week, Monday to Friday, for the full internship.
ConsultingRisk, Regulatory & Legal Advisory
No H1B Sponsorship

About the job

Requirements
  • Currently enrolled in an undergraduate or graduate program at an accredited university focused on law, public policy, public health, political science, health economics, or a related field.
  • Must be permanently authorized to work in the United States and not require employment visa sponsorship at application or in the future. Students on CPT, OPT, or STEM OPT generally do not meet this requirement unless eligible for an alternative long-term status without company sponsorship.
  • Must remain enrolled in an accredited college or university throughout the internship.
  • Must be able to relocate to the office location and work 40 hours per week, Monday through Friday, for the full internship duration.
Responsibilities
  • Track and analyze federal legislation, hearings, and policy trends affecting the biopharmaceutical industry.
  • Assist with developing policy briefing materials, summaries, presentations, and internal memoranda.
  • Attend Congressional hearings, meetings, and policy briefings as appropriate, and prepare summaries for internal stakeholders.
  • Research topics including drug pricing, artificial intelligence in drug development and manufacturing, and Medicare and Medicaid policy.
Desired Qualifications
  • Demonstrated interest in health law or policy, life sciences, or the biopharmaceutical industry.
  • Ability to synthesize complex information into clear, concise written and verbal inputs.
  • Clear academic or career direction toward the biopharmaceutical industry and health policy.
  • Ability to produce clear, concise policy memoranda, briefing materials, impact assessments, and white papers for diverse audiences.
  • Familiarity with artificial intelligence tools and agents for research, analysis, and productivity enhancement.
  • Basic knowledge of U.S. healthcare programs and stakeholders, including Medicare, Medicaid, 340B, pharmacy benefit managers, and pharmaceutical reimbursement systems.
  • Science background, such as biology, chemistry, or life sciences coursework, alongside a policy or political science major.
  • Interest in U.S. domestic policy and global or international health policy.
  • Proficiency in Microsoft Office Suite, including Word, PowerPoint, and Excel, for research, writing, and presentations.
  • Ability to interact effectively with senior stakeholders and external partners.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...